Phaseline

Targets › SSTR2

SSTR2 (Somatostatin receptor type 2): drug programs, companies and trials

47 programs from 41 companies in 86 trials: 40 Phase 2, 23 Phase 1, 18 Phase 3, 5 Phase 4; Oncology, Gastroenterology, Metabolic and endocrine; next expected readout Nov 2026.

Receptor for somatostatin-14 and -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. (UniProt, P30874)

Open in Phaseline: the race on SSTR2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University Hospital, AntwerpSomatostatin
Somatostatin receptor agonist
SSTR5, SSTR2, SSTR4, SSTR1, SSTR3Phase 4Gastroenteropancreatic Neuroendocrine TumorApr 2029
Helsinki University Central HospitalPasireotide
Somatostatin receptor 5 agonist; Somatostatin receptor 2 agonist; Somatostatin receptor 1 agonist
SSTR5, SSTR2, SSTR1, SSTR3Phase 4Pancreatic FistulaDec 2029
Weill Medical College of Cornell UniversityGa68-DOTATATE-PET/MRI
Somatostatin receptor 2 (SSTR2) targeted PET/MRI imaging agent
SSTR2Phase 4CNS TumorsDec 2038
CamurusCAM2029
Somatostatin receptor agonist (octreotide subcutaneous depot)
SSTR2Phase 3Gastro-enteropancreatic Neuroendocrine Tumor; Polycystic Liver DiseaseNov 2026
HTALutetium Oxodotreotide Lu-177
Somatostatin receptor binding agent
SSTR5, SSTR2, SSTR4, SSTR1, SSTR3Phase 3NETS Ga68 Lu177Nov 2026
Jiangsu HengRui MedicineLutetium (177Lu) Oxodotreotide Injection
Somatostatin receptor 2 (SSTR2)-targeting peptide radionuclide therapy
SSTR2Phase 3Advanced Gastroenteropancreatic Neuroendocrine TumorDec 2026
RayzeBioRYZ101
Actinium-225 labeled somatostatin receptor agonist (SSTR-targeting radiopharmaceutical)
SSTR2Phase 3GEP-NET; SCLC,Extensive Stage; Metastatic Breast CancerDec 2026
ITM Solucin177Lu-edotreotide PRRT
Peptide receptor radionuclide therapy (PRRT) targeting somatostatin receptors
SSTR2, SSTR5Phase 3Neuroendocrine TumorsJun 2027
Crinetics PharmaceuticalsPaltusotine
Somatostatin receptor 2 agonist
SSTR2Phase 3Carcinoid SyndromeAug 2027
Advanced Accelerator ApplicationsLutetium Oxodotreotide Lu-177
Somatostatin receptor binding agent
SSTR5, SSTR2, SSTR4, SSTR1, SSTR3Phase 3Gastro-enteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumors; Digestive System Neuroendocrine Tumor G1; Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs) …Oct 2027
Debiopharm InternationalDebio 4126
somatostatin analog (somatostatin receptor agonist)
SSTR2, SSTR5Phase 3AcromegalyJun 2028
Novartis[177Lu]Lu-DOTA-TATE
SSTR2-targeted radioligand therapy with lutetium-177
SSTR2Phase 3Somatostatin Receptor Positive (SSTR+); Metastatic Neuroendocrine Prostate CancerDec 2028
Sinotau Pharmaceutical GroupLutetium Oxodotreotide Lu-177
Somatostatin receptor binding agent
SSTR5, SSTR2, SSTR4, SSTR1, SSTR3Phase 3Neuroendocrine TumorsDec 2028
Grupo Espanol de Tumores Neuroendocrinos177Lu-edotreotide
Somatostatin receptor 2 (SSTR2) agonist labeled with lutetium-177 for radionuclide therapy
SSTR2Phase 3Neuroendocrine TumorsMar 2029
SWOG Cancer Research NetworkLanreotide
Somatostatin receptor 5 agonist; Somatostatin receptor 2 agonist
SSTR5, SSTR2Phase 3Pancreatic CarcinomaApr 2029
Washington University School of MedicineSomatostatin
Somatostatin receptor agonist
SSTR5, SSTR2, SSTR4, SSTR1, SSTR3Phase 3Neuroendocrine NeoplasmNov 2034
Lund University Hospital177Lu-DOTATOC
somatostatin receptor 2 (SSTR2) targeting radiolabeled somatostatin analog
SSTR2Phase 3Neuroendocrine Tumors–
HTA68Ga-DOTATATE Injection
Somatostatin receptor 2 (SSTR2) agonist/imaging agent
SSTR2Phase 3NETs; Healthy (Controls); Metastic Thyroid Cancer; ACTH–
University Hospital, Grenoble68Ga-DOTATOC
Somatostatin receptor 2 (SSTR2) targeting PET imaging agent
SSTR2Phase 3Breast Cancer Metastatic–
Tine Gregersen, MDLu-177-DOTATOC
Somatostatin receptor 2 (SSTR2) targeting radiopharmaceutical; Lu-177 is a beta-emitting r
SSTR2Phase 2Neuroendocrine NeoplasmDec 2026
The Netherlands Cancer InstituteSomatostatin
Somatostatin receptor agonist
SSTR5, SSTR2, SSTR4, SSTR1, SSTR3Phase 2Neuroendocrine TumorsJan 2027
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS177Lu-DOTATOC
Somatostatin receptor-targeted radionuclide therapy with lutetium-177
SSTR1, SSTR2, SSTR3, SSTR4, SSTR5Phase 2Neuroendocrine TumorsJan 2027
Memorial Sloan Kettering Cancer CenterPasireotide
Somatostatin receptor 5 agonist; Somatostatin receptor 2 agonist; Somatostatin receptor 1 agonist
SSTR5, SSTR2, SSTR1, SSTR3Phase 2Prolactin-Producing Pituitary TumorFeb 2027
Antonio FojoLanreotide
Somatostatin receptor 5 agonist; Somatostatin receptor 2 agonist
SSTR5, SSTR2Phase 2ParagangliomaMar 2027
University Hospital, BordeauxLUTATHERA® by intra-arterial hepatic (IAH) injection
Radiolabeled somatostatin analog (177Lu-DOTA-TATE) with intra-arterial hepatic delivery to
SSTR2Phase 2Neuroendocrine TumorMar 2027
Sinotau Pharmaceutical GroupLutetium[177Lu] Oxodotreotide Injection
Somatostatin receptor 2 (SSTR2)-targeting peptide receptor radionuclide therapy (PRRT) wit
SSTR2Phase 2Advanced Neuroendocrine NeoplasmJun 2027
National Cancer Institute (NCI)Lu-177-DOTATATE
Somatostatin receptor 2 (SSTR2) targeting radiopharmaceutical; Lu-177 is a beta-emitting r
SSTR2Phase 2Pheochromocytoma; Gastroenteropancreatico TumorsJul 2027
University of Alberta68Ga-HA-DOTATATE
Somatostatin receptor (SSR) PET imaging tracer - gallium-68 labeled somatostatin analog
SSTR1, SSTR2, SSTR3, SSTR5Phase 2Neuroendocrine TumorsAug 2027
Australasian Gastro-Intestinal Trials GroupSomatostatin
Somatostatin receptor agonist
SSTR5, SSTR2, SSTR4, SSTR1, SSTR3Phase 2Neuroendocrine TumorsSep 2027
University Hospital HeidelbergPasireotide
Somatostatin receptor 5 agonist; Somatostatin receptor 2 agonist; Somatostatin receptor 1 agonist
SSTR5, SSTR2, SSTR1, SSTR3Phase 2Desmoplastic Small Round Cell TumorOct 2027
Centre de recherche du Centre hospitalier universitaire de Sherbrooke68Ga-DOTATATE
Somatostatin receptor 2 (SSTR2) agonist radiopharmaceutical
SSTR2Phase 2NeuroblastomaDec 2027
Tata Memorial HospitalTerbium 161 DOTATATE
Auger-emitter peptide receptor radionuclide therapy targeting somatostatin receptors
SSTR2Phase 2Neuroendocrine Neoplasms (Tumours)Feb 2028
CSPC ZhongQi Pharmaceutical TechnologyOctreotide
Somatostatin receptor agonist
SSTR5, SSTR2, SSTR4, SSTR1, SSTR3Phase 2Gastroenteropancreatic Neuroendocrine Tumors; Pancreas Head CancerAug 2028
Universitaire Ziekenhuizen KU Leuven[18F]AlF-NOTA-octreotide
Somatostatin receptor 2 (SSTR2) agonist PET tracer; octreotide labeled with fluorine-18 al
SSTR2Phase 2Stroke (CVA) or TIASep 2029
Orano Med212Pb-DOTAMTATE (AlphaMedix)
Somatostatin receptor 2 (SSTR2)-targeting alpha-emitter therapy; radiolabeled octreotide a
SSTR2Phase 2Neuroendocrine TumorsDec 2030
National Cancer Institute (NCI)68-Gallium DOTATATE
somatostatin receptor 2 agonist for PET/CT imaging
SSTR2Phase 2VHL Pancreatic Neuroendocrine TumorsJan 2036
RECORDATI GROUPPasireotide Diaspartate
Somatostatin receptor 5 agonist; Somatostatin receptor 2 agonist; Somatostatin receptor 1 agonist
SSTR5, SSTR2, SSTR1, SSTR3Phase 2Post-Bariatric Hypoglycemia–
Melanoma and Skin Cancer Trials LimitedLutetium-177 (177Lu)-DOTATATE
Peptide receptor radionuclide therapy (PRRT) targeting somatostatin receptor 2
SSTR2Phase 1Metastatic Merkel Cell CarcinomaDec 2026
University Medical Center Groningen[68Ga]Ga-DOTA-TOC
Somatostatin receptor 2 (SSTR2) imaging agent
SSTR2Phase 1Nasopharyngeal Carcinoma (NPC)Dec 2026
University Hospital, Basel, Switzerland177Lu-DOTA-JR11
Radiolabeled somatostatin antagonist; 177Lu-emitting radiopharmaceutical targeting somatos
SSTR2, SSTR5Phase 1MeningiomaDec 2026
Joshua PalmerActinium Ac 225 DOTATATE RYZ101
Somatostatin receptor 2 (SSTR2) targeted alpha emitter; Ac-225 labeled somatostatin analog
SSTR2Phase 1Recurrent MeningiomaDec 2026
RayzeBioRYZ401
Ac-225-based targeted alpha therapy for somatostatin receptor expression
SSTR1, SSTR2, SSTR3, SSTR4, SSTR5Phase 1GEP-NETFeb 2027
Nanjing Chia-tai Tianqing PharmaceuticalNTQ6179
somatostatin receptor subtype 2 (SSTR2) agonist
SSTR2Phase 1AcromegalyApr 2027
NovartisLutetium Oxodotreotide
Somatostatin receptor binding agent
SSTR5, SSTR2, SSTR4, SSTR1, SSTR3Phase 1Glioblastoma; Extensive Stage Small Cell Lung CancerMay 2027
National Health Research Institutes, TaiwanLanreotide
Somatostatin receptor 5 agonist; Somatostatin receptor 2 agonist
SSTR5, SSTR2Phase 1Neuroendocrine Tumors,GastroenteropancreaticAug 2027
Jason WinnickSomatostatin
Somatostatin receptor agonist
SSTR5, SSTR2, SSTR4, SSTR1, SSTR3Phase 1Hypoglycemia; IatrogenicMay 2028
University Hospital, Basel, Switzerland61Cu-NODAGA-LM3
somatostatin receptor 2 (SSTR2) ligand labeled with copper-61 radioisotope for PET imaging
SSTR2Phase 1Neuroendocrine TumorsJun 2028

Conditions

Neuroendocrine Tumors (17) Meningioma (3) Metastatic Pancreatic Neuroendocrine Tumor (3) Acromegaly (2) Gastroenteropancreatic Neuroendocrine Tumor (2) Neuroendocrine Neoplasm (2) Recurrent Meningioma (2) Gastro-enteropancreatic Neuroendocrine Tumor (2) GEP-NET (2) Gastroenteropancreatic Neuroendocrine Tumors (2) Somatostatin Receptor Positive (SSTR+) (1) Metastatic Neuroendocrine Prostate Cancer (1)

Modalities

small molecule (19), protein or peptide (14), mixed (11), antibody (1)

Companies

Novartis (2) National Cancer Institute (NCI) (2) Sinotau Pharmaceutical Group (2) University Hospital, Basel, Switzerland (2) HTA (2) RayzeBio (2) Universitaire Ziekenhuizen KU Leuven (1) ITM Solucin (1) Nanjing Chia-tai Tianqing Pharmaceutical (1) Weill Medical College of Cornell University (1) University Hospital, Antwerp (1) University Hospital Heidelberg (1) Orano Med (1) Washington University School of Medicine (1) Antonio Fojo (1) Tata Memorial Hospital (1) Joshua Palmer (1) Camurus (1) Jason Winnick (1) Helsinki University Central Hospital (1)

Related targets

SSTR5 (23) SSTR1 (17) SSTR3 (17) SSTR4 (12)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.